Table 1.
Patient characteristics
| Gefitinib (n = 55) | Erlotinib (n = 22) | |
|---|---|---|
| Sex, n (%) | ||
| Male | 19 (35) | 11 (50) |
| Female | 36 (65) | 11 (50) |
| Median age, years (range) | 71 (46–91) | 71 (47–83) |
| ECOG PS, n (%) | ||
| 0–1 | 39 (71) | 18 (82) |
| ≧2 | 16 (29) | 4 (18) |
| TNM stage, n (%) | ||
| 3B | 3 (5) | 1 (5) |
| 4 | 43 (78) | 16 (73) |
| Recurrence | 9 (16) | 5 (23) |
| Previous chemotherapy regimen, n (%) | ||
| 0 | 44 (80) | 9 (41) |
| 1 | 9 (16) | 7 (32) |
| ≧2 | 2 (4) | 6 (27) |
| Brain metastasis, n (%) | ||
| 0 | 40 (73) | 10 (45) |
| ≧1 | 15 (27) | 12 (55) |
| Radiotherapy for brain metastasis before EGFR-TKI treatment, n (%) | 4 (7) | 6 (27) |
| WBRT | 1 (2) | 1 (4) |
| SRT | 3 (5) | 5 (23) |
| EGFR mutation, n (%) | ||
| Exon19 del | 24 (44) | 6 (27) |
| Exon21 L858R | 29 (53) | 15 (68) |
| Minor | 2 (4) | 1 (5) |
| Dose reduction or intermittent administration, n (%) | 13 (24) | 10 (45) |
| Best response, n (%) | ||
| CR | 0 (0) | 0 (0) |
| PR | 24 (44) | 11 (50) |
| SD | 20 (36) | 9 (41) |
| PD | 4 (7) | 1 (5) |
| Unknown | 7 (13) | 1 (5) |
| The reason of EGFR-TKI discontinuation, n (%) | ||
| Disease progression | 36 (65) | 17 (77) |
| CNS progression | 10 (18) | 2 (9) |
| Adverse event | 5 (9) | 2 (9) |
| Other | 7 (13) | 1 (5) |
| Ongoing | 7 (13) | 2 (9) |
ECOG PS Eastern Cooperative Oncology Group performance status, WBRT whole brain radiotherapy, SRT stereotactic radiotherapy, CR complete response, PR partial response, SD stable disease, PD progressive disease, CNS central nervous system, EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor